Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma with Severe Renal Impairment
2016-000433-51Phase 2Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Overall response rate. Started Jul 2016; status: terminated.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-000433-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000433-51.